Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors.
The treatment of cancer by genetic manipulation of either the tumor itself or the patient as a whole offers new avenues for the treatment of otherwise refractory cancers. Gene therapy seeks to correct underlying genetic defects in malignant tissue or to augment the host defense response or to promote selectivity of other therapies. Many innovative and exciting genetic targets have been recently identified. However, the field as a whole is still constrained by limitations of gene delivery. The most common vector for gene delivery is modified adenovirus. In this review, we survey a sampling of current therapeutic approaches that depend upon adenoviral delivery vehicles and outline the advantages and disadvantages of this vector system.
US Oncology, Mary Crowley Medical Research Center, Baylor University Medical Center, 3535 Worth Street, Collins Building, 5th Floor, Dallas, TX 75246, USA.
John
J
Nemunaitis
Casey
C
Cunningham
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D019008:Drug Resistance, Neoplasm; D005786:Gene Expression Regulation / Q000235:genetics; D018390:Gene Targeting; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D019076:Transgenes / Q000235:genetics